Epstein-Barr virus-specific T-cell therapy - Atara Biotherapeutics/Memorial Sloan-Kettering Cancer Center

Drug Profile

Epstein-Barr virus-specific T-cell therapy - Atara Biotherapeutics/Memorial Sloan-Kettering Cancer Center

Alternative Names: allogenic ATA188; Anti-CD19 antigen receptor-expressing allogeneic cytotoxic T lymphocytes; ATA-129; EBV targeted T-cell therapy - Atara/MSKCC; EBV-CTL - Atara/MSKCC; EBV-specific T-cells - Atara/MSKCC; Epstein-Barr virus specific cytotoxic T-lymphocytes - Atara/MSKCC

Latest Information Update: 05 Jan 2017

Price : $50

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA)
  • Class T lymphocyte cell therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lymphoproliferative disorders
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Lymphoproliferative disorders

Most Recent Events

  • 17 Mar 2017 Atara Biotherapeutics plans a phase I trial of allogenic ATA 188 for Multiple sclerosis in USA
  • 03 Jan 2017 Atara Biotherapeutics announces intention to submit Conditional MAA with the EMA in 2018
  • 12 Dec 2016 Atara Bio plans phase III MATCH and ALLELE trials for Epstein-Barr virus associated lymphoproliferative disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top